Thera-SAbDab

DANVILOSTOMIG

>   Structural Summary
TherapeuticDanvilostomig
Target 1CTLA4/CD152
Heavy Chain 1QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS
Light Chain 1EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK
100% seqID Fv 1 Structure5tru [Fvs: HL, hl], 5xj3 [Fvs: AB, DE, GH, JK], 6jc2 [Fvs: HL], 6rp8 [Fvs: HL, hl], 7elx [Fvs: HL]
99% seqID Fv 1 StructureNone
95-98% seqID Fv 1 Structure7su0 [Fvs: HL, IM], 7su1 [Fvs: HL]
Target 2PDCD1/CD279/PD1
Heavy Chain 2EVQLVESGGGLVQPGGSLRLSCTASGFSLSSYAMSWVRQAPGKGLEYIGYIGDTTGIAYASWANGRFTISKDNTKNTVDLQMNSLRAEDTAVYYCARGWSYLDIWGQGTLVTVSS
Light Chain 2ALVMTQSPSSLSASVGDRVTITCQASQNIYSNLAWYQQKPGKVPKLLIYQASTLASGVPSRFSGSGYGTDFTLTISSLQPEDVATYYCQGGYYSAALNTFGGGTKVEIK
100% seqID Fv 2 StructureNone
99% seqID Fv 2 StructureNone
95-98% seqID Fv 2 StructureNone
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Danvilostomig.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 97.79%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 101 102 103 104 105 106 107 108 109 110 111 112 113
danvilostomig_Fv1 Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S S Y T M H W V R Q A P G K G L E W V T F I S Y D G N N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L R A E D T A I Y Y C A R T G W L G P F D Y W G Q G T L V T V S S
7su0 Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S H Y T M H W V R Q A P G K G L E W V T F I S Y D G H N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L R A E D T A I Y Y C A R T G W L G P F D Y W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 30A 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
danvilostomig_Fv1 E I V L T Q S P G T L S L S P G E R A T L S C R A S Q S V G S S Y L A W Y Q Q K P G Q A P R L L I Y G A F S R A T G I P D R F S G S G S G T D F T L T I S R L E P E D F A V Y Y C Q Q Y G S S P W T F G Q G T K V E I K
7su0 E I V L T Q S P G T L S L S P G E R A T L S C R A S Q E V G E S E L A W Y Q Q K P G Q A P R L L I Y G A F S R A T G I P D R F S G S G S G T D F T L T I S R L E P E D F A V Y Y C Q Q Y G S S P W T F G Q G T K V E I K
Sequence identity: 97.35%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 101 102 103 104 105 106 107 108 109 110 111 112 113
danvilostomig_Fv1 Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S S Y T M H W V R Q A P G K G L E W V T F I S Y D G N N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L R A E D T A I Y Y C A R T G W L G P F D Y W G Q G T L V T V S S
7su1 Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S H Y T M H W V R Q A P G K G L E W V T F I S Y D G H N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L R A E D T A I Y Y C A R H G W L G P F D Y W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 30A 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
danvilostomig_Fv1 E I V L T Q S P G T L S L S P G E R A T L S C R A S Q S V G S S Y L A W Y Q Q K P G Q A P R L L I Y G A F S R A T G I P D R F S G S G S G T D F T L T I S R L E P E D F A V Y Y C Q Q Y G S S P W T F G Q G T K V E I K
7su1 E I V L T Q S P G T L S L S P G E R A T L S C R A S Q E V G E S E L A W Y Q Q K P G Q A P R L L I Y G A F S R A T G I P D R F S G S G S G T D F T L T I S R L E P E D F A V Y Y C Q Q Y G S S P W T F G Q G T K V E I K
>   Metadata
FormatBispecific Mixed mAb and scFv
IsotypeG1;na
Highest Clinical Trial (Aug '24)Phase-II
Estimated StatusDiscontinued
Recorded Developmental Technology
INN Year Proposed2022
INN Year RecommendedNone
Companies InvolvedSichuan Baili Pharmaceutical, SystImmune
Conditions Approvedna
Conditions ActiveCervical cancer, Colorectal cancer, Gastric cancer, HER2 negative breast cancer, Nasopharyngeal cancer, Non-small cell lung cancer, Oesophageal cancer, Small cell lung cancer, Solid tumours, Squamous cell cancer, Urogenital cancer
Conditions Discontinuedna
NotesDanvilostomig Fv1,Ipilimumab, Sovipostobart, and Tazlestobart all have the same sequence

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy